Fleury S.A.

São Paulo Stock Exchange FLRY3.SA

Fleury S.A. Price to Sales Ratio (P/S) on January 14, 2025: 0.78

Fleury S.A. Price to Sales Ratio (P/S) is 0.78 on January 14, 2025, a -46.02% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Fleury S.A. 52-week high Price to Sales Ratio (P/S) is 1.45 on January 15, 2024, which is 85.25% above the current Price to Sales Ratio (P/S).
  • Fleury S.A. 52-week low Price to Sales Ratio (P/S) is 0.78 on January 13, 2025, which is -0.63% below the current Price to Sales Ratio (P/S).
  • Fleury S.A. average Price to Sales Ratio (P/S) for the last 52 weeks is 1.12.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
São Paulo Stock Exchange: FLRY3.SA

Fleury S.A.

CEO Ms. Jeane Mike Tsutsui
IPO Date Dec. 17, 2009
Location Brazil
Headquarters Avenida General Valdomiro de Lima, 508
Employees 27,000
Sector Health Care
Industries
Description

Fleury S.A., together with its subsidiaries, provides medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics, and ophthalmology areas in Brazil. The company operates through three segments: Diagnostic Medicine, Integrated Medicine, and Dental. It provides laboratory and image exam, diagnostic information, check-up and reference laboratory, genomics, clinic day, center of infusions, dental imaging exam, dental radiology, and diagnostic imaging services. The company also offers Saúde I, a digital healthcare platform that provides services, including teleconsultations, medical, diagnostic medicine exams, and procedures; and corporate solutions and face-to-face primary care, as well as solutions for physicians with digital office and medical education. It operates 284 customer service units and 31 hospital-based units under the Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, a+ and Diagmax, a+, IRN / CPC, Diagnosis a+, a+BA, and Pretti and Bioclinic brand names. The company was founded in 1926 and is headquartered in São Paulo, Brazil.

Similar companies

ABEV3.SA

Ambev S.A.

USD 1.85

0.28%

EGIE3.SA

Engie Brasil Energia S.A.

USD 5.71

0.61%

MDIA3.SA

M. Dias Branco S.A. Indústria e Comércio de Alimentos

USD 3.22

1.38%

WEGE3.SA

WEG S.A.

USD 8.71

-0.05%

StockViz Staff

January 15, 2025

Any question? Send us an email